Zelgen Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
1,055
- Stock Symbol
-
688266
- Investments
-
1
- Share Price
-
$11.08
- (As of Friday Closing)
Zelgen General Information
Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Contact Information
Website
www.zelgen.comCorporate Office
- No. 209, Chenfeng Road
- Kunshan, Jiangsu 215300
- China
Corporate Office
- No. 209, Chenfeng Road
- Kunshan, Jiangsu 215300
- China
Zelgen Stock Performance
As of 20-Nov-2026, Zelgen’s stock price is $11.08. Its current market cap is $2.93B with 265M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.08 | $11.59 | $10.88 - $23.58 | $2.93B | 265M | 3.94M | $0.31 |
Zelgen Financials Summary
As of 30-Sep-2026, Zelgen has a trailing 12-month revenue of $254M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,096,414 | 3,369,826 | 2,083,922 | 1,780,524 |
| Revenue | 254,406 | 112,703 | 74,275 | 54,621 |
| EBITDA | 78,484 | (20,803) | (17,956) | (36,899) |
| Net Income | 82,513 | (22,659) | (19,209) | (39,376) |
| Total Assets | 493,370 | 424,369 | 411,585 | 407,303 |
| Total Debt | 83,514 | 161,899 | 142,360 | 125,321 |
Zelgen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zelgen Comparisons
Industry
Financing
Details
Zelgen Competitors (14)
One of Zelgen’s 14 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
Zelgen Patents
Zelgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026124659-A1 | Dicarbonyl inhibitor, preparation method therefor and use thereof | Pending | 13-Dec-2024 | ||
| WO-2026021499-A1 | Haloalkylene substituted cycloalkyl or heterocyclic inhibitor, and preparation method therefor and use thereof | Pending | 24-Jul-2024 | ||
| US-20250388703-A1 | Multi-specific molecules and mentod of use and making thereof | Pending | 20-Jun-2024 | ||
| WO-2025208342-A1 | Method for preparing high-purity and low-residue recombinant human thrombin and use thereof | Pending | 02-Apr-2024 | ||
| WO-2025162477-A1 | Multispecific antibody containing lrrc15 antigen-binding domain | Pending | 04-Feb-2024 |
Zelgen Signals
Zelgen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Zelgen Investments (1)
Zelgen’s most recent deal was a PE Growth/Expansion with Gene Chem for . The deal was made on 30-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gene Chem | 30-Jul-2020 | PE Growth/Expansion | Laboratory Services (Healthcare) |
Zelgen ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
43.13 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Zelgen FAQs
-
When was Zelgen founded?
Zelgen was founded in 2009.
-
Where is Zelgen headquartered?
Zelgen is headquartered in Kunshan, China.
-
What is the size of Zelgen?
Zelgen has 1,055 total employees.
-
What industry is Zelgen in?
Zelgen’s primary industry is Drug Discovery.
-
Is Zelgen a private or public company?
Zelgen is a Public company.
-
What is Zelgen’s stock symbol?
The ticker symbol for Zelgen is 688266.
-
What is the current stock price of Zelgen?
As of 20-Nov-2026 the stock price of Zelgen is $11.08.
-
What is the current market cap of Zelgen?
The current market capitalization of Zelgen is $2.93B.
-
What is Zelgen’s current revenue?
The trailing twelve month revenue for Zelgen is $254M.
-
Who are Zelgen’s competitors?
Ability Pharma, Genentech, Gilead, Merck & Co., and Pfizer Pakistan are some of the 14 competitors of Zelgen.
-
What is Zelgen’s annual earnings per share (EPS)?
Zelgen’s EPS for 12 months was $0.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process